BioNTech (BNTX) PT Lowered to $132 at Canaccord
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts BNTX Hot Sheet
Price: $91.29 +0.13%
Rating Summary:
16 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 31
Rating Summary:
16 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 31
Join SI Premium – FREE
Canaccord analyst William Maughan lowered the price target on BioNTech (NASDAQ: BNTX) to $132.00 (from $136.00) while maintaining a Buy rating.
You May Also Be Interested In
- Abbott Labs (ABT) PT Lowered to $125 at BTIG
- The Blackstone Group (BX) PT Lowered to $130 at BMO Capital
- BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
